Report updated on 11th September, 2021: Global Animal Pharmaceuticals Market 2021 (Includes Business Impact of COVID-19)
Global Animal Pharmaceuticals Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global animal pharmaceuticals market report has been segmented on the basis of product type, animal type, and region.
Request Covid - 19 Impact
The global Animal Pharmaceuticals market size was valued at USD $15.05 billion in 2020 and is projected to reach USD $31.49 billion by 2030 is anticipated to expand at a CAGR of 7.65% over the forecast period from 2020 to 2030.
Global Animal Pharmaceuticals Market: Overview
Animal pharmaceuticals are used to treat or prevent diseases and infections. Animal pharmaceuticals are available in a variety of forms, which allows veterinarian to manage needed medications, such as liquids, pills, injections, and powders. Animal pharmaceuticals are regulated by the Food and Drug Administration (FDA) Center for veterinary medicines.
Global Animal Pharmaceuticals Market: Dynamics
Increasing intake of meat and milk products in routine diet, growing zoonotic and food borne diseases, and trend of pet adoption are some key factors expected to drive growth of target market. In addition, growing health concern related to animals and increasing healthcare expenses are some factors estimated to fuel growth of target market.
Recent trend observed in target market is number of animal healthcare NGOs are increasing. In addition, research and development activities related to productivity improvements along with growth of generic and over-the-counter (OTC) drugs for animal care are some of key trends witnessed in the global market.
However, stringent rules and regulations in animal testing and restrictions imposed by regulatory authorities may hamper growth of global market over the forecast period.
Global Animal Pharmaceuticals Market: Segment Analysis
Among the product type segments, the vaccine segment is expected to account for major share in terms of revenue in the global market.
Among the animal type segments, the production animals segment is estimated to register significant growth rate over the forecast period.
Global Animal Pharmaceuticals Market: Region Analysis
Geographically, North America is expected to dominate global animal pharmaceuticals market, owing to factors such as high standard of living and increasing awareness regarding diseases associated with livestock and companion animals. In addition, growing demand for pet ownership and presence of major players in the region are some of aspects acting as a major contributor for growth of target market.
Also, changing lifestyle in the developing countries such as China and India, has increased the adoption of production animals, which supports growth of the animal pharmaceuticals market. On the other hand, markets in Europe and Middle East & Africa are expected to contribute significant revenue share in the global market due to increasing animal-sourced food as well as increasing demand for proper care and treatment of the animals. The animal pharmaceuticals market is estimated to benefit from the opportunities in terms of new legislations for animal pharmaceuticals.
Positive support and efforts from numerous government & associations such as Food and Drug Administration (FDA), Federal Food, Drug, and Cosmetic Act (FFDCA), American Pet Products Association (APPA) and American Veterinary Medical Association (AVMA) are estimated to boost market growth over the forecast period. According to US Food and Drug Administration, new drugs and certain biologics approved by FDA in 2018 to treat cats, dogs, and livestock.
Global Animal Pharmaceuticals Market Segmentation:
By Product Type:
- Veterinary Drugs
By Animal Type:
- Companion Animals (Canine, Feline, and Equine)
- Production Animals (Livestock and Poultry)
Key Market Players included in the report:
- Bayer AG
- Boehringer Ingelheim GmbH
- Eli Lilly and Company (Elanco)
- Merck & Co. Inc.
- Perrigo Company plc
- Phibro Animal Health Corporation
- Vetoquinol S.A.
- Virbac SA,
- Zoetis Inc.
Below are the key development related to Animal Pharmaceuticals Market in 2020 and 2021.
June 2021: MSD Animal Health to Acquire Assets of LIC Automation Ltd. Automated Technology Enhances Dairy Farm Management. Builds on Strong MSD Animal Health Commitment to New Zealand Farmers. Complements Broad MSD Animal Health Portfolio of Medicines, Vaccines and Technology Solutions. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), announced its intention to acquire the assets of LIC Automation Ltd. (“LICA”), from New Zealand-based, farmer-owned cooperative Livestock Improvement Corporation Ltd. (“LIC”). LICA is a leader in automation and technology for the dairy industry. Specific terms of the agreement were not disclosed. Source
June 2021: Elanco Acquires Pet Therapeutics Company. Greenfield-based Elanco Animal Health Inc. (NYSE: ELAN) says it has acquired California-based Kindred Biosciences Inc. (Nasdaq: KIN) in a deal valued at approximately $440 million. KindredBio is a biopharmaceutical company focused on developing novel pet therapeutics. Elanco says the acquisition further accelerates Elanco’s expansion in the companion pet health market. The KindredBio website says it is trying to narrow a chasm between human and animal medicine. It says drugs from the human pharmaceuticals field could possibly be developed for companion animals, such as human drugs that have been abandoned. Source
August 2020: Elanco Closes Acquisition of Bayer Animal Health. Scale and capabilities of the combined company position Elanco for the long term as a leader in the attractive, durable animal health industry. Combines Elanco’s longstanding focus on the veterinarian with Bayer Animal Health’s direct-to-consumer expertise to open new opportunities to fuel growth. Enables Elanco to capitalize on emerging trends accelerated by the COVID-19 pandemic, including pet owners’ increased desire to access care and products via online, retail, telemedicine, and direct to the doorstep. Transaction strengthens Elanco’s Innovation, Portfolio, Productivity (IPP) strategy, advancing portfolio transformation to balance mix between the pet health and farm animal businesses. Transaction valued at close at $6.89 billion, funded by $5.17 billion in cash and 72.9 million shares to Bayer. Elanco Animal Health Incorporated (NYSE: ELAN) announced it has closed the acquisition of Bayer Animal Health. The transaction, valued at $6.89 billion, expands Elanco’s scale and capabilities, positioning the company for the long term as a leader in the attractive, durable animal health industry. Source
August 2020: Merck Animal Health Completes Acquisition of IdentiGEN. Strategic Transaction Enhances Farm-to-Table Animal Traceability Solutions for Livestock and AquacultureMADISON, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), announced the completion of its acquisition of IdentiGEN, a leader in DNA-based animal traceability solutions for Livestock and Aquaculture from MML Growth Capital Partners Ireland. Specific terms of the agreement were not disclosed. IdentiGEN’s technology combines each species’ unique DNA (deoxyribonucleic acid) and data analytics to provide an evidence-based animal traceability solution, called DNA TraceBack®, to accurately and precisely trace beef, seafood, pork and poultry that is verifiable from farm-to-table. Source
August 2020: Wedgewood Pharmacy Completes Acquisition of Wildlife Pharmaceuticals and Its Subsidiary ZooPharm; Appoints New Wildlife General Manager. Wedgewood Pharmacy has completed the acquisition of Wildlife Pharmaceuticals, Inc., Windsor, Colorado, and its wholly-owned pharmacy subsidiary, ZooPharm, Laramie, Wyoming. The companies serve veterinarians and patients in the wildlife and zoo markets. ZooPharm is a veterinary compounding pharmacy that provides veterinary-anesthesia and pain-management medications to care for non-domestic species, resident wildlife, captive exotic breeds, and companion animals. Source
July 2020: Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals. Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal Category with Comprehensive, Continuous Parasite Protection. Complements Merck Animal Health’s Broad Portfolio of Vaccines. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), announced the completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP). Source
April 2020: Heska Corporation Completes Acquisition of scil animal care to Create a Global Leader in Veterinary Point-of-Care Diagnostics. Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announces the completion of the acquisition of scil animal care company GmbH ("scil") from Covetrus, Inc. for US $110 million in cash, subject to customary closing adjustments (NASDAQ: CVET; "Covetrus") (the "Acquisition"). The Acquisition, which was first announced, represents a key milestone in the Companys long-term strategic plan. scil has been a proven European leader since 1998 in providing veterinary point-of-care laboratory and imaging diagnostics, with headquarters in Germany and operations in France, Italy, Spain and Canada. This acquisition creates a leading global veterinary diagnostics company, servicing millions of pets through tens of thousands of veterinarians and active point of care analyzers around the world. Source